Nautilus Biotechnology installed its first external single‑molecule protein analysis instrument at the Buck Institute to study tau proteoforms in neurodegenerative disease, marking the company’s step toward early access deployments of its platform. Nautilus claims single‑molecule scale and high proteoform resolution, positioning the system for targeted applications in neurology research. At the same time, Alida Biosciences introduced Tri‑Mod, a multiplex epitranscriptomics assay that detects m6A, inosine and pseudouridine in one workflow and has begun beta testing with early customers. Together these launches spotlight investor and researcher interest in next‑generation proteomic and RNA modification tools that aim to unlock new biomarker and target spaces.